152 related articles for article (PubMed ID: 24145784)
1. Bypassing T cell 'exhaustion'.
Göthert JR
Nat Immunol; 2013 Nov; 14(11):1114-6. PubMed ID: 24145784
[No Abstract] [Full Text] [Related]
2. Hypoxia-inducible factors enhance the effector responses of CD8(+) T cells to persistent antigen.
Doedens AL; Phan AT; Stradner MH; Fujimoto JK; Nguyen JV; Yang E; Johnson RS; Goldrath AW
Nat Immunol; 2013 Nov; 14(11):1173-82. PubMed ID: 24076634
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia-inducible factor activity promotes antitumor effector function and tissue residency by CD8+ T cells.
Liikanen I; Lauhan C; Quon S; Omilusik K; Phan AT; Bartrolí LB; Ferry A; Goulding J; Chen J; Scott-Browne JP; Yustein JT; Scharping NE; Witherden DA; Goldrath AW
J Clin Invest; 2021 Apr; 131(7):. PubMed ID: 33792560
[TBL] [Abstract][Full Text] [Related]
4. VHL promotes immune response against renal cell carcinoma via NF-κB-dependent regulation of VCAM-1.
Labrousse-Arias D; Martínez-Alonso E; Corral-Escariz M; Bienes-Martínez R; Berridy J; Serrano-Oviedo L; Conde E; García-Bermejo ML; Giménez-Bachs JM; Salinas-Sánchez AS; Sánchez-Prieto R; Yao M; Lasa M; Calzada MJ
J Cell Biol; 2017 Mar; 216(3):835-847. PubMed ID: 28235946
[TBL] [Abstract][Full Text] [Related]
5. Expression of hypoxia-inducible factor 1alpha, hypoxia-inducible factor 2alpha, and von Hippel-Lindau protein in epithelial ovarian neoplasms and allelic loss of von Hippel-Lindau gene: nuclear expression of hypoxia-inducible factor 1alpha is an independent prognostic factor in ovarian carcinoma.
Osada R; Horiuchi A; Kikuchi N; Yoshida J; Hayashi A; Ota M; Katsuyama Y; Melillo G; Konishi I
Hum Pathol; 2007 Sep; 38(9):1310-20. PubMed ID: 17555795
[TBL] [Abstract][Full Text] [Related]
6. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
[TBL] [Abstract][Full Text] [Related]
7. Modified Hypoxia-Inducible Factor Expression in CD8
Veliça P; Cunha PP; Vojnovic N; Foskolou IP; Bargiela D; Gojkovic M; Rundqvist H; Johnson RS
Cancer Immunol Res; 2021 Apr; 9(4):401-414. PubMed ID: 33602720
[TBL] [Abstract][Full Text] [Related]
8. From genes to metabolomics in renal cell carcinoma translational research.
Mulders PF
Eur Urol; 2013 Feb; 63(2):252-3. PubMed ID: 23182551
[No Abstract] [Full Text] [Related]
9. The Tale of Two Hypoxia-Inducible Factors in Renal Cell Carcinoma.
Nanus DM; Gudas LJ
Eur Urol; 2016 Apr; 69(4):658-659. PubMed ID: 26431912
[No Abstract] [Full Text] [Related]
10. Hypoxia-inducing factor (HIF)-1α-derived peptide capable of inducing cancer-reactive cytotoxic T lymphocytes from HLA-A24
Minami T; Matsumura N; Sugimoto K; Shimizu N; De Velasco M; Nozawa M; Yoshimura K; Harashima N; Harada M; Uemura H
Int Immunopharmacol; 2017 Mar; 44():197-202. PubMed ID: 28110220
[TBL] [Abstract][Full Text] [Related]
11. Re: Targeting Renal Cell Carcinoma with a HIF-2 Antagonist.
Shenoy N; Pagliaro L
Eur Urol; 2018 Feb; 73(2):304-305. PubMed ID: 29102314
[No Abstract] [Full Text] [Related]
12. Re: Targeting Renal Cell Carcinoma with a HIF-2 Antagonist.
Ferguson JE; Matin SF
Eur Urol; 2017 Jun; 71(6):987. PubMed ID: 28237787
[No Abstract] [Full Text] [Related]
13. Kidney cancer: HIF-2α - a new target in RCC.
Thoma C
Nat Rev Urol; 2016 Nov; 13(11):627. PubMed ID: 27670614
[No Abstract] [Full Text] [Related]
14. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein.
Cockman ME; Masson N; Mole DR; Jaakkola P; Chang GW; Clifford SC; Maher ER; Pugh CW; Ratcliffe PJ; Maxwell PH
J Biol Chem; 2000 Aug; 275(33):25733-41. PubMed ID: 10823831
[TBL] [Abstract][Full Text] [Related]
15. Hypoxia-inducible factors, hypoxia, and tumor angiogenesis.
Gruber M; Simon MC
Curr Opin Hematol; 2006 May; 13(3):169-74. PubMed ID: 16567961
[TBL] [Abstract][Full Text] [Related]
16. Action of hypoxia-inducible factor in liver and kidney from mice with Pax8-rtTA-based deletion of von Hippel-Lindau protein.
Mathia S; Paliege A; Koesters R; Peters H; Neumayer HH; Bachmann S; Rosenberger C
Acta Physiol (Oxf); 2013 Mar; 207(3):565-76. PubMed ID: 23384425
[TBL] [Abstract][Full Text] [Related]
17. HIF hydroxylation and the mammalian oxygen-sensing pathway.
Safran M; Kaelin WG
J Clin Invest; 2003 Mar; 111(6):779-83. PubMed ID: 12639980
[No Abstract] [Full Text] [Related]
18. Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway.
Carroll VA; Ashcroft M
Cancer Res; 2006 Jun; 66(12):6264-70. PubMed ID: 16778202
[TBL] [Abstract][Full Text] [Related]
19. Cobalt inhibits the interaction between hypoxia-inducible factor-alpha and von Hippel-Lindau protein by direct binding to hypoxia-inducible factor-alpha.
Yuan Y; Hilliard G; Ferguson T; Millhorn DE
J Biol Chem; 2003 May; 278(18):15911-6. PubMed ID: 12606543
[TBL] [Abstract][Full Text] [Related]
20. Hydrogen sulfide inhibits hypoxia- but not anoxia-induced hypoxia-inducible factor 1 activation in a von hippel-lindau- and mitochondria-dependent manner.
Kai S; Tanaka T; Daijo H; Harada H; Kishimoto S; Suzuki K; Takabuchi S; Takenaga K; Fukuda K; Hirota K
Antioxid Redox Signal; 2012 Feb; 16(3):203-16. PubMed ID: 22004513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
